以岭药业品牌怎么样 申请店铺

我要投票 以岭药业在中草药行业中的票数:245 更新时间:2025-05-11
以岭药业是哪个国家的品牌?「以岭药业」是 石家庄以岭药业股份有限公司 旗下著名品牌。该品牌发源于河北,由创始人吴相君在2001期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力以岭药业品牌出海!将品牌入驻外推网,定制以岭药业品牌推广信息,可以显著提高以岭药业产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

以岭药业怎么样

国家重点高新技术企业--石家庄以岭药业股份有限公司由中国工程院吴以岭院士创建,在他的领导下,以岭药业始终坚持以科技为先导,以市场为龙头的科技创新发展战略,创立"理论-科研-新药-生产-营销"五位一体的独特运营模式,建立起以中医络病理论创新为指导的新药研发创新技术体系。

在以岭药业的发展历程中,凝聚了一大批科研、管理、生产、营销精英,包括归国专家、外籍专家、博士、硕士及各类高职人才,为河北医科大学培养博士、硕士研究生,被国家人事部批准为博士后科研工作站。

以岭药业以络病理论创新带动中医药产业化,运用现代高新技术研发现代中药、西药、和生物药,研发国家专利新药9个,覆盖心脑血管疾病、感冒呼吸疾病、肿瘤、糖尿病及其并发症等重大疾病领域。通过国家GMP认证的中药生产线、通过欧盟认证的化学制剂生产车间具有年产值达50亿的生产能力。以岭药业为国家创新型企业、中国制药工业50强,以岭商标成为中国驰名商标。

国家科技部前领导曾赞誉五位一体的发展模式为"我国中医药科技成果产业化的创举"。

以岭药业立足国内、接轨国际,在石家庄、北京大兴、密云建立了三个国际标准的科研生产基地,通过了欧盟、新西兰等GMP认证。科研、生产、质检、贸易、管理人才全部具有国际化背景,构建了符合国际药品标准的生产、质控体系。依靠现代高新技术与设备和完善的药品生产质量控制体系,生产高品质中药与西药。产品已经出口到英国、美国、西班牙、韩国、日本、俄罗斯、新西兰等许多国家。

位于北京生物工程与医药产业基地的北京以岭药业,占地210亩,为国家重点高新技术企业,主要生产面向国际市场的植物药、保健品、膳食补充剂。

位于北京密云的北京以岭生物按照欧美GMP标准建设,主要生产面向国际市场的激素、肿瘤类药物和具有自主知识产权的新制剂。

Shijiazhuang Yiling Pharmaceutical Co., Ltd, a national key high-tech enterprise, was founded by Academician Wu Yiling of Chinese Academy of engineering. Under his leadership, Yiling pharmaceutical always adheres to the development strategy of scientific and technological innovation with science and technology as the guide and market as the leader, creates a unique operation mode of "theory research new medicine production marketing" and establishes a theoretical innovation of traditional Chinese medicine collateral disease as the reference New drug R & D innovation technology system. In the development process of Yiling pharmaceutical industry, a large number of scientific research, management, production and marketing elites, including returned experts, foreign experts, doctors, masters and all kinds of higher vocational talents, have been gathered, training doctors and masters for Hebei Medical University, and approved by the Ministry of human resources as post doctoral research workstation. Lingyao promotes the industrialization of traditional Chinese medicine with the innovation of collateral disease theory, develops modern Chinese medicine, western medicine and biological medicine with modern high and new technology, and develops 9 new national patent drugs, covering the major disease fields such as cardio cerebrovascular disease, cold and respiratory disease, tumor, diabetes and its complications. The production line of traditional Chinese medicine certified by national GMP and the chemical production workshop certified by European Union have an annual output value of 5 billion. Take Ling pharmaceutical as a national innovative enterprise and top 50 pharmaceutical industry in China, and take Ling trademark as a well-known trademark in China. Former leaders of the Ministry of science and technology of the people's Republic of China once praised the five in one development mode as "the pioneering work of industrialization of scientific and technological achievements of traditional Chinese medicine". Based on domestic and international standards, Yiling pharmaceutical has established three international standard research and production bases in Shijiazhuang, Beijing Daxing and Miyun, and has passed GMP certification of EU, New Zealand, etc. The talents of scientific research, production, quality inspection, trade and management all have international background, and the production and quality control system in line with international drug standards has been established. Relying on modern high-tech and equipment and perfect quality control system of drug production, we can produce high-quality traditional Chinese medicine and Western medicine. The products have been exported to the United Kingdom, the United States, Spain, South Korea, Japan, Russia, New Zealand and many other countries. Located in Beijing bioengineering and pharmaceutical industry base, Beijing Yiling pharmaceutical, covering an area of 210 mu, is a national key high-tech enterprise, which mainly produces plant medicine, health care products and dietary supplements for the international market. Beijing Yiling biology, located in Miyun, Beijing, is built in accordance with European and American GMP standards. It mainly produces hormones, tumor drugs and new preparations with independent intellectual property rights for the international market.

本文链接: https://brand.waitui.com/887854f10.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

理想L7累计交付量突破30万辆

5月10日,理想汽车宣布,理想L7累计交付量突破300,000辆。(财联社)

40分钟前

“爱达·地中海号”邮轮首航深圳

5月9日,“爱达·地中海号”邮轮抵达深圳国际邮轮母港,并于当晚从深圳首航。今年秋季,“爱达·地中海号”将以深圳为母港运营特色航线,覆盖中国香港,以及日本、越南、菲律宾等目的地。爱达邮轮是中国邮轮自主品牌,其运营的国产大型邮轮“爱达·魔都号”也将于2026年在深圳首航。(e公司)

40分钟前

长春光机所光电突触器件研究取得新进展

中国科学院长春光学精密机械与物理研究所(下称“长春光机所”)的科研人员开发出一种紫外光电突触器件和一种光电突触晶体管,这两项成果分别为先进人工视觉系统和神经形态计算视觉的发展提供了新的技术路径。紫外光电突触器件由长春光机所特种发光科学与技术全国重点实验室黎大兵、孙晓娟研究员领导的研究团队成功开发。(e公司)

40分钟前

我国科学家实现基于主动光学强度干涉的合成孔径成像

中国科学技术大学潘建伟、张强、徐飞虎等人联合美国麻省理工学院、中国科学院西安光学精密机械研究所等单位,首次提出并实验验证了主动光学强度干涉技术合成孔径技术,实现了对1.36公里外毫米级目标的高分辨成像。实验系统的成像分辨率较干涉仪中的单台望远镜提升约14倍。该成果5月9日在国际学术期刊《物理评论快报》发表。(财联社)

40分钟前

海光信息杨鸿轩:医疗国产化进入实战期,好用比性能更重要

36氪获悉,在CHIMA 2025大会现场,海光信息副总裁杨鸿轩表示,医疗行业信息化进入实战阶段,对底层算力平台的要求不仅是性能强,更要“好用”和“易用”。海光高度重视生态链建设,联合超5000家产业链伙伴,从芯片、整机到操作系统、数据库、应用软件,构建了完整的产业生态体系,推动全场景应用适配。杨鸿轩指出,医疗行业专业信息化人手紧张,对平台“无感迁移”和“一站式支撑”的需求更高。他强调,海光将持续加大在医疗国产化领域的投入,携手生态伙伴深化技术协同与应用优化,助力医院构建稳健、高效的国产化信息系统基础。

40分钟前

本页详细列出关于以岭药业的品牌信息,含品牌所属公司介绍,以岭药业所处行业的品牌地位及优势。
咨询